MDRX · As filed with the SEC
Veradigm income statement, by fiscal year
The statement as Veradigm presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Revenue | 594,410,000 | 588,017,000 | 1,503,037,000 | 1,502,700,000 | 1,632,611,000 | 1,617,841,000 |
| Software delivery, Support and Maintenance | — | — | 916,186,000 | 914,662,000 | 1,010,993,000 | 1,011,624,000 |
| Client services | — | — | 586,851,000 | 588,038,000 | 621,618,000 | 606,217,000 |
| Payer & Life Science | — | 122,090,000 | — | — | — | — |
| Provider | 473,065,000 | 465,927,000 | — | — | — | — |
| Software delivery, Support and Maintenance | — | — | 278,551,000 | 287,954,000 | 319,140,000 | 315,102,000 |
| Client services | — | — | 486,221,000 | 530,652,000 | 595,310,000 | 584,666,000 |
| Amortization of software development and acquisition-related assets | — | — | 118,700,000 | 118,399,000 | 107,874,000 | 96,682,000 |
| Provider | — | 232,758,000 | — | — | — | — |
| Payer & Life Science | — | 46,839,000 | — | — | — | — |
| Cost of revenue | 292,165,000 | 279,597,000 | 883,472,000 | 937,005,000 | 1,022,324,000 | 996,450,000 |
| Gross profit | 302,245,000 | 308,420,000 | 619,565,000 | 565,695,000 | 610,287,000 | 621,391,000 |
| Selling, general and administrative expenses | 269,406,000 | 169,201,000 | 313,814,000 | 389,941,000 | 400,808,000 | 432,849,000 |
| Research and development | 108,255,000 | 97,889,000 | 193,671,000 | 206,061,000 | 245,443,000 | 258,736,000 |
| Asset impairment charges | — | 7,549,000 | 11,772,000 | 74,969,000 | 10,837,000 | 58,166,000 |
| Goodwill impairment charge | — | — | 0 | 0 | 25,700,000 | 13,466,000 |
| Amortization of intangible and acquisition-related assets | — | 60,884,000 | 23,109,000 | 25,604,000 | 27,188,000 | 26,558,000 |
| Impairment of goodwill and other assets | 108,218,000 | — | — | — | — | — |
| Amortization of intangibles | 11,027,000 | — | — | — | — | — |
| Income (loss) from operations | (194,661,000) | (27,103,000) | 77,199,000 | (130,880,000) | (99,689,000) | (168,384,000) |
| Loss on debt extinguishment | (17,632,000) | — | — | — | — | — |
| Interest expense | (15,045,000) | (6,354,000) | (13,166,000) | (34,104,000) | (43,172,000) | (50,914,000) |
| Interest income | 16,231,000 | — | — | — | — | — |
| Insurance recoveries | 5,000,000 | — | — | — | — | — |
| Other income (expense), net | (8,230,000) | (21,676,000) | 87,666,000 | 54,000 | (138,904,000) | 69,000 |
| Gain (loss) on sale of businesses, net | — | 0 | 8,370,000 | 0 | 0 | 172,258,000 |
| Impairment of long-term investments | — | (7,575,000) | 0 | (1,575,000) | (651,000) | (15,487,000) |
| Equity in net income (loss) of unconsolidated investments | — | (1,143,000) | 1,757,000 | 17,194,000 | 665,000 | 259,000 |
| Impairment of long-term investments | (575,000) | — | — | — | — | — |
| Income (loss) from continuing operations before income taxes | 214,912,000 | (63,851,000) | 161,826,000 | (149,311,000) | (281,751,000) | (62,199,000) |
| Income tax benefit (provision) | (69,492,000) | 43,807,000 | (27,851,000) | 16,692,000 | 43,340,000 | 18,983,000 |
| Income (loss) from consolidated continuing operations, net of tax | (284,404,000) | (20,044,000) | 133,975,000 | (132,619,000) | (238,411,000) | (43,216,000) |
| (Loss) income from discontinued operations | — | — | (15,000) | 71,448,000 | 75,235,000 | 2,501,000 |
| Equity in net loss of unconsolidated subsidiaries, net of tax | (7,175,000) | — | — | — | — | — |
| Income (loss) from continuing operations, net of tax | (291,579,000) | — | — | — | — | — |
| Loss from discontinued operations | 0 | (7,122,000) | — | — | — | — |
| Loss on sale of discontinued operations | 0 | (10,327,000) | 647,000 | 1,156,504,000 | 0 | 500,471,000 |
| Income tax effect on discontinued operations | 0 | (48,969,000) | (169,000) | (394,926,000) | (19,426,000) | (51,949,000) |
| Loss from discontinued operations, net of tax | 0 | (66,418,000) | 463,000 | 833,026,000 | 55,809,000 | 451,023,000 |
| Net income (loss) | (291,579,000) | (86,462,000) | 134,438,000 | 700,407,000 | (182,602,000) | 407,807,000 |
| Net loss attributable to noncontrolling interests | 37,000 | — | 0 | 0 | 424,000 | 4,527,000 |
| Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations | — | — | — | 0 | 0 | (48,594,000) |
| Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders | — | — | 134,438,000 | 700,407,000 | (182,178,000) | 363,740,000 |
| Net income (loss) attributable to Veradigm Inc. | (291,542,000) | — | — | — | — | — |
| Basic | ||||||
| Continuing operations | (2.7) | (0.18) | 1.03 | (0.83) | (1.43) | (0.22) |
| Discontinued operations | 0 | (0.59) | 0 | 5.23 | 0.33 | 2.29 |
| Net basic earnings (loss) per common share | (2.7) | (0.77) | 1.03 | 4.4 | (1.1) | 2.07 |
| Diluted | ||||||
| Continuing operations | (2.7) | (0.18) | 0.97 | (0.83) | (1.43) | (0.22) |
| Discontinued operations | 0 | (0.59) | 0 | 5.23 | 0.33 | 2.29 |
| Net income (loss) per share - Diluted | (2.7) | (0.77) | 0.97 | 4.4 | (1.1) | 2.07 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.